News

ISA Pharmaceuticals and Prosensa receive Mibiton funding for peptide manufacturing facility

May 12, 2011
Leiden, The Netherlands, April 26th , 2011 - ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, today announced that Mibiton supports IS...
Read more

InteRNA Technologies Strengthens its R&D Team

April 29, 2011
Nijmegen/Utrecht, The Netherlands, April 29th, 2011 - InteRNA Technologies B.V., a biopharmaceutical company developing pathway targeted microRNA (miRNA)-based therapeutics for cancer, is pleased to announce...
Read more

ISA Pharmaceuticals embarks on EUR 4 million Cancer Vaccine development track awarded by CTMM

March 22, 2011
ISA Pharmaceuticals B.V., a leader in the development of immunotherapeutic products for oncology and infectious diseases, announced that CTMM, an agency of the Dutch Ministry of Economic Affairs, has awarded...
Read more

Merus receives € 0.75 million grant for the discovery and development of Oligoclonics™ antibody therapy for colon cancer.

January 05, 2011
Utrecht, The Netherlands, January 5th 2010 ‐ Merus announced today that it has received a € 0.75 million grant for the discovery and development of an antibody combination therapy for colon cancer using its...
Read more

Press release Innovation Credit_InteRNA

November 16, 2010
Date: 16 November, 2010 InteRNA Technologies Awarded EUR 1.3 million Innovation Credit from Dutch Government Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company developing path...
Read more

KWF Kankerbestrijding reikt KWO-prijzen 2010 uit.

October 12, 2010
6 mln euro voor tumorimmunologie en langetermijngevolgen kankerbehandeling 7 december 2010 - Prof.dr.ir. Floor van Leeuwen (NKI-AVL), prof.dr. Kees Melief (LUMC) en prof.dr Carl Figdor (UMC St. Radboud) ont...
Read more

Dr. Wolfgang Berthold joins Supervisory Board Merus

September 20, 2010
Utrecht, the Netherlands (September 20, 2010) - Dutch biopharmaceutical company Merus announced today that Dr. Wolfgang (Wolf) Berthold has joined its Supervisory Board. "We are delighted to appoint Wolf Ber...
Read more

InteRNA Technologies announces establishment of Scientific Advisory Board

July 08, 2010
Utrecht (the Netherlands) - InteRNA Technologies B.V., a biopharmaceutical company focusing on the development of intelligent microRNA (miRNA)-based therapeutics for cancer, announces the establishment of it...
Read more

Bachem to supply ISA Pharmaceuticals with finished dosage forms immunotherapeutic HPV-SLP® for phase III clinical trials

June 02, 2010
Bubendorf, Switzerland and Leiden, Netherlands, Bachem (SIX: BANB) and ISA Pharmaceuticals B.V. today announced the conclusion of an agreement for the manufacture of the active ingredients and the supply of...
Read more

Merus Announces Publication of the Generation of Single, Clonal Cell lines

June 02, 2010
Merus BV today announced the April 16, 2010 online publication of data by J. de Kruif et. al., in the 'Early View' section of the journal Biotechnology and Bioengineering that demonstrate for the first time...
Read more

Syntarga Announces Additional Antibody-Drug Conjugate Collaborations

May 31, 2010
Syntarga B.V., the emerging Antibody- Drug Conjugate (ADC) company, announces today that it entered into three additional research collaborations since its March 2010 press release. These latest agreements c...
Read more

Syntarga Announces Two Antibody-Drug Conjugate Collaborations with Top-tier Biopharmaceutical Companies

March 03, 2010
Syntarga B.V., the emerging Antibody-Drug Conjugate (ADC) company, announces today that it entered into research collaborations with two undisclosed top-15 pharma companies. These latest agreements, adding t...
Read more

Merus closes EUR 21.7 million Series B financing and enters option agreement with the Novartis Option Fund

January 29, 2010
Merus, a biopharmaceutical company located in Utrecht, The Netherlands, announced today that it has closed a €21.7 million ($30.7 million) Series B financing round led by new investors the Novartis Option Fu...
Read more

Merus receives EuroTransBio Grant

December 15, 2009
Merus BV, a biopharmaceutical company focused on the discovery and development of mixtures of human therapeutic antibodies, today announced that it has received a grant worth € 0.67 million for the developme...
Read more

ISA Pharmaceuticals announces NEJM publication on VIN phase II data

November 11, 2009
New England Journal of Medicine Publishes a highly Successful Clinical Study by Leiden University Medical Center and ISA Pharmaceuticals B.V. with a therapeutic HPV vaccine in patients with premalignant vulv...
Read more

Orca Therapeutics receives VCN License

September 30, 2009
ORCA Therapeutics BV a biopharmaceutical company in the field of virotherapy, announces that it has obtained an exclusive license from VCN Biosciences SL of Gelida (Barcelona), Spain, to their T1 oncolytic a...
Read more

Syntarga Announces Patent Grant for SpaceLink Technology for Antibody-Drug Conjugation

July 16, 2009
Syntarga B.V. announces that as of today patents have been granted for its proprietary SpaceLink Technology in Europe (EP 1370298 B1), the United States (US 7,223,837), India, China, New Zealand and Australi...
Read more

ISA Pharmaceuticals names Nigel Crockett Business Development director

July 09, 2009
ISA Pharmaceuticals B.V., the Dutch clinical stage biopharmaceutical company focusing on the development of therapeutic vaccines against cancer, today announced the further strengthening of its management te...
Read more

InteRNA Technologies joins TI Pharma by signing new project to develop novel anti-angiogenic miRNA-based therapeutics

July 06, 2009
Three new small and medium enterprises (SMEs), Syncom, Synvolux Therapeutics and InteRNA Technologies, have joined the public-private partnership TI Pharma by participating in two new projects. The two proje...
Read more

Kees Melief, CSO of ISA Pharmaceuticals, receives prestigious Coley Award

June 05, 2009
FOR IMMEDIATE RELEASE Scientific & Corporate Leaders in Immunology, Tumor Immunology to be Honored at Cancer Research Institute 23rd Annual Awards Dinner 2009 Grace and Coley Award Winners Announced May 29,...
Read more

Home > News > Archive

© 2024 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds